

Two pandemics to fight: metabolic surgery and its effects on COVID-19 and obesity

Dos pandemias a combatir: cirugía metabólica y sus efectos sobre la COVID-19 y obesidad

Enrique Cervantes-Pérez^{1,2,3*}, Gabino Cervantes-Guevara^{3,4}, Alejandro González-Ojeda⁵, Clotilde Fuentes-Orozco⁵, Sol Ramírez-Ochoa¹, Guillermo A. Cervantes-Cardona⁶,

Blanca M. Torres-Mendoza⁶, Gabino Cervantes-Pérez¹, and Eduardo Gómez-Sánchez⁷

¹Department of Internal Medicine, Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara; ²Health Sciences University Center, Universidad de Guadalajara, Guadalajara; ³Department of Welfare and Sustainable Development, Centro Universitario del Norte, Universidad de Guadalajara, Colotlán; ⁴Department of Gastroenterology, Hospital Civil de Guadalajara "Fray Antonio Alcalde". Guadalajara; ⁵Biomedical Research Unit 02, Specialties Hospital, Western National Medical Center, Mexican Institute of Social Security, Guadalajara; ⁶Department of Philosophical, Methodological and Instrumental Disciplines, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara; ⁷Division of Basic Health Disciplines, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Jalisco, Mexico

To the editor

As of April 6, 2022, almost 500 million confirmed cases of COVID-19, including more than 6.1 million deaths have been reported to the World Health Organization (WHO)¹. Obesity, hypertension (HT), and type 2 diabetes have all been identified as predictors of poor outcomes in COVID-19 infection (T2DM). Thrombotic events were identified as a contributing factor in death. Patients with obstructive sleep apnea (OSA) are more vulnerable to respiratory infections and have worse results.

Obesity is a disaster when it comes to COVID-19 infection and has been linked to an increased risk of HT, T2DM, OSA, and other metabolic disorders. These patients have a higher thromboembolic risk than the overall population².

The COVID-19 pandemic is expected to exacerbate the obesity epidemic. Restriction of physical activity, limited availability to healthy food, deterioration of mental health, and deterioration of economic situation all contribute to the acceleration of obesity. The studies from the United States of America and the United Kingdom that obesity has increased the prevalence of COVID-19 among the younger population are concerning³.

Metabolic surgery (MS) is a well-established method of treating obesity. However, all elective MS procedures have been postponed by national and international societies (International Federation for the Surgery of Obesity and Metabolic Disorders). Delaying surgery adds to the illness burden in these patients. As a result of societal stigma and economical constraints, MS is underutilized. In addition, there were concerns that MS changes immunity, putting these individuals at a greater risk of acquiring COVID-19.

There is no evidence that individuals undergoing MS surgery are at a higher risk of COVID-19 infection than the general population. Patients with MS who are obese lose fat stores, ameliorate their comorbidities, and so become less prone to severe outcomes if infected with COVID-19⁴.

COVID-19, according to the WHO, may never go away. We must strategize to combat both the COV-ID-19 and obesity pandemics at the same time. MS is the solution to both problems. When states aim to recommence elective health-care activities, it should

*Correspondence:

Enrique Cervantes-Pérez

E-mail: enrique.cervantes@academico.udg.mx

Date of reception: 07-04-2022 Date of acceptance: 08-04-2022 DOI: 10.24875/CIRU.22000206 Cir Cir. 2023;91(3):437-438 Contents available at PubMed www.cirugiaycirujanos.com

0009-7411/© 2022 Academia Mexicana de Cirugía. Published by Permanyer. This is an open access article under the terms of the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

be given top attention. MS is already known to be cost-effective and pays for itself in a matter of years. Furthermore, major multinational prospective studies on the link between obesity, MS, and COVID-19 should be conducted.

Funding

No external funding was received to support this work.

Conflicts of interest

The authors declare that there are no competing interests.

Responsabilidades éticas

Protección de personas y animales. Los autores declaran que para esta investigación no se han

realizado experimentos en seres humanos ni en animales.

Confidencialidad de los datos. Los autores declaran que en este artículo no aparecen datos de pacientes.

Derecho a la privacidad y consentimiento informado. Los autores declaran que en este artículo no aparecen datos de pacientes.

References

- WHO Coronavirus Disease (COVID-19) Dashboard. Geneva: World Health Organization; 2022. Available from: https://www.covid19.who.int [Last accessed on 2022 Apr 06].
- Rubino F, Cohen RV, Mingrone G, le Roux CW, Mechanick JI, Arterburn DE, et al. Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. Lancet Diabetes Endocrinol. 2020;8:640-8.
- Kass DA, Duggal P, Cingolani O. Obesity could shift severe COVID-19 disease to the younger ages. Lancet. 2020;395:1544-5.
- Yang W, Wang C, Shikora S, Kow L. Recommendations for metabolic and bariatric surgery during the COVID-19 pandemic from IFSO. Obes Surg. 2020;30:2071-3.